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BACKGROUND 
                   Bleomycin is one of the important  chemotherapy commonly given for 
the treatment of Hodgkin lymphoma and germ-cell tumours, the most highly curable 
cancers . But  bleomycin can cause severe life-threatening lung injury, which ranges 
from hypersensitivity pneumonitis and bronchiolitis obliterans organizing 
pneumonia (BOOP) to acute interstitial pneumonia and progressive pulmonary 
fibrosis  
 Hence early diagnosis , treatment, and prevention of limiting toxicities such 
as bleomycin-induced lung injury, is very important. This study aims at of earlier 
prediction of bleomycin induced lung toxicity in  hodgkin’s lymphoma & germcell 
tumours 
AIMS AND OBJECTIVES:To identify the patients developing lung toxicity 
for Bleomycin in hodgkin’s lymphoma and germcell tumourby PFT and HRCT.                   
MATERIALS AND METHODS: 
STUDY POPULATION: The study is conducted on 30 patients admitted to 
Government Rajaji Hospital & Madurai Medical College during the study period 
from March 2018 to August 2018.Inclusion criteria:Newly diagnosed Hodgkins 
lymphoma and germ cell tumour patients with age more than 18 years confirmed by 
histopathological examination and immunohistochemistry.Exclusion criteria: 
Underlying lung disease .METHOD OF DATA COLLECTION:Hodgkin’s 
lymphoma and germ cell tumour patients of varying age and sex were selected their 
consent was taken. The history was elicited. Age, height weight were recorded. 
Thorough clinical examination were carried out. DESIGN OF STUDY:Prospective  
and observational study.PERIOD OF STUDY:6 months (March 2018 to August 
2018)The performance of baseline PFT was carried out. In all the patients relevant 
information will be collected in a predesigned proforma. The patients are selected 
based on clinical examinations, histopathological examination and 
immunohistochemistry. The patients are followed over a period of 6 months with 
pulmonary function test and HRCT at regular intervals.Complete blood count,Liver 
function test,Renal function test, Sputum AFB,Sputum Culture and 
sensitivity,HPE,IHC, Chest X ray,PFT, HRCT will be done in all patients to screen 
for pre existing lung disease. 
RESULT:Totally 30 patients among which 18 hodgkin’s lymphoma and 12 germ 
cell tumour patients admitted in the Govt Rajaji Hospital were studied for 
bleomycin induced lung toxicity during march 2018 to August 2018. 
Selected patients were free from previous lung disease as screened by PFT 
and HRCT. After completing the course of chemotherapy for HL and GCT patients 
they were assessed. 12 patients developed symptoms among which 9 had dry cough 
and 3 had dyspnoea.All patients were subjected to PFT at the end of the treatment. 9 
of them developed abnormal PFT in the form of obstruction in 5 patients, restrictive 
pattern in 3 patients and mixed form in 1 patient. When HRCT was repeated for these 
patients they did not show any abnormality. 
Since bleomycin toxicity is not only dose dependent these patients have to 
be further followed up from earlier course of treatment to  a minimum of 2 years for 
earlier identification of bleomycin induced toxicity. 
 
CONCLUSION    Bleomycin-induced lung injury is a major pulmonary 
toxicity. The mortality of this complication is high, ranging from 10 to 20%, and 
significantly impacts quality of life and five-year overall survival. The diagnosis of 
interstitial lung disease and BIP is particularly challenging and often depends on 
clinical, radiological, and cytological findings. Progress in understanding the 
mechanisms behind the therapeutic efficacy and unwanted toxicity of bleomycin, as 
well as elucidation of its biosynthetic pathway, may lead to the development of 
agents capable of preventing or treating BIP. Until then, physicians administrating 
bleomycin should be aware of potential lung toxicity, especially in the presence of 
risk factors.  
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